Real-World Evidence (RWE) in Pharma: From Data to Access

Map EHR structure and biases to turn transactions into analysis-ready real-world evidence. Blend structured data with narrative notes, enforce quality checks, and document lineage for regulator-ready datasets.

Explore how claims data illuminate utilization and cost endpoints in real-world evidence, comparing open and closed streams, and show how linkage to clinical records enables timely, scalable insights.

Explore how registries and pragmatic trials bridge real-world evidence and randomized research, enabling faster, broader insights into natural history, effectiveness, and safety within clinical practice.

Explore wearables, apps, and PROs as real-world data streams linked to records and claims, with governance, validation, and equity to support outcomes and market access.

Improve real world evidence credibility by enforcing data completeness, conformance, and provenance, with automated checks and a clear lineage from source systems to analysis.

Compare cohort and case-control designs for real-world evidence from administrative data, using transparent pre-specified plans and methods like propensity weighting to manage bias.

Frame target trial emulation by defining a time-zero protocol with baseline covariates and a clear estimand, then align real-world data to that design.

Map trials along a pragmatic–explanatory spectrum to balance control and realism, using purpose-driven design, transparent decisions, and registry-based methods to inform regulators, payers, and clinicians.

Build external and synthetic control arms from registries and electronic records, align eligibility, endpoints, and follow-up to mirror a single-arm trial and accelerate credible answers.

Learn to name bias and design around it, using exchangeability, clear adjustment, and fair follow up to compare like with like; use diagrams and diagnostics for trustworthy real world evidence.

Master time-to-event analysis and survival methods for real-world data, accounting for censoring, competing risks, delayed entry, and real-world endpoints to inform care and policy.

Observe how interrupted time series and difference-in-differences transform real-world policy data into credible counterfactuals, revealing level shifts, slope changes, and policy impact.

Learn instrumental variables and causal forests to identify heterogeneous treatment effects in real-world evidence, and translate findings for regulators and payers with credible, actionable guidance.

Perform sensitivity and quantitative bias analyses to quantify unmeasured confounding and missing data, using E values and tipping point analysis to strengthen real-world evidence for care decisions.

Set up a self-contained, reproducible R and Python lab using Conda, renv, and Docker. Isolate, document, and automate your workflow for regulatory-grade real-world evidence.

Exploit the Omop data model and Fhir interoperability to enable federated, large-scale analytics and real world evidence through real-time data exchange.

Reproduce an FDA sentinel real-world evidence study comparing dabigatran and warfarin in Medicare patients using active-comparator new-user design, high dimensional propensity scores, IPTW, and a Cox model.

Transform one-off analyses into validated, reusable pipelines by enforcing version control, automated testing, data quality checks, parameterization, and containerized reproducibility for regulatory use.

Discover how the FDA real-world evidence framework turns principles into a practical playbook, emphasizing relevance, reliability, fit-for-purpose design, pre-specified protocols, and traceability with concurrent controls.

Align your real-world evidence with EMA, MHRA, and PMDA expectations by standardizing data to a shared schema, ensuring provenance, reproducibility, and auditability across federated analyses and containerized workflows.

Align your submission with a crisp protocol, a defined sap, and full traceability to prove reproducibility, minimize bias, and show provenance from data to analysis.

Master real world evidence design for health technology assessment by emulating trials with registries and claims, linking clinical effect to value through transparent, budget-conscious modeling.

Establish a culture of inspection readiness by tracing data lineage, freezing environments, and maintaining auditable run logs, lineage diagrams, and git commits with container image digests for reproducible results.

Frame early discovery with patient reality using real world evidence to define population, prognostic factors, and actionable biomarkers. Align screening design and target validation with longitudinal data and genomic context.

Real-world data transforms feasibility from guesswork into cartography, guiding computable phenotypes, pre-screening, and site selection to accelerate enrollment with diverse, data-backed decisions.

Real world evidence drives post-marketing commitments and label expansion by leveraging registries, curated electronic records, and real-world cohorts to evaluate safety, durability, and access.

Learn how pharmacovigilance transforms spontaneous reports, claims, and EHR data into timely safety signals using longitudinal designs and disproportionality methods.

Real world evidence informs cost-effectiveness and budget-impact models by integrating real world data on persistence, switching, and resource use from EHRs, claims, and registries.

Turn burden into a human story by integrating real world data, claims, and electronic records. Map epidemiology: incidence, prevalence, costs, and quality of life to inform transparent pricing.

Craft value dossiers by weaving trial data with real world evidence, linking narrative visuals to reproducible code and economic models, enabling payers to test scenarios and pathways.

Navigate HIPAA and GDPR with practical privacy safeguards to enable cross-border real-world evidence, using anonymisation, pseudonymisation, and expert determination while leveraging data privacy frameworks, DPIA, and federated analytics.

Explains how broad and dynamic consent enable secondary use of real-world data through computable preferences and transparent governance, turning consent into an operating system for ethical evidence.

Explore governance models for pharma data sharing, translating contracts into human-readable, auditable agreements, and selecting patterns like centralized lake, data environments, or federated analytics to speed science while protecting privacy.

Expose and mitigate bias in real world data by improving capture, detection, and governance across data, models, and reporting to deliver equitable health insights.

Discover how transformer models unlock unstructured clinical notes into structured variables for real world evidence, enabling credible NLP pipelines trusted by regulators.

Explore federated and privacy-preserving analytics to derive outcomes without sharing raw data, using secure enclaves, secure aggregation, and differential privacy to accelerate real-world evidence.

Real-time RWE dashboards deliver continuous, in-workflow guidance from signals and models integrated into the EHR, enabling timely, privacy-preserving decisions with transparent reasoning.

Emulate a target trial to design a defensible real-world study, crafting a protocol and analysis plan and delivering a regulatory-ready dossier.